Bristol-Myers Squibb (NYSE:BMY) Shares Sold by EP Wealth Advisors LLC

EP Wealth Advisors LLC cut its holdings in shares of Bristol-Myers Squibb (NYSE:BMYFree Report) by 18.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 449,695 shares of the biopharmaceutical company’s stock after selling 101,485 shares during the period. EP Wealth Advisors LLC’s holdings in Bristol-Myers Squibb were worth $23,074,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. Johnson Investment Counsel Inc. lifted its stake in Bristol-Myers Squibb by 0.7% in the 3rd quarter. Johnson Investment Counsel Inc. now owns 127,714 shares of the biopharmaceutical company’s stock valued at $7,412,000 after buying an additional 852 shares in the last quarter. Excalibur Management Corp lifted its stake in Bristol-Myers Squibb by 5.8% in the 3rd quarter. Excalibur Management Corp now owns 21,037 shares of the biopharmaceutical company’s stock valued at $1,221,000 after buying an additional 1,161 shares in the last quarter. Financial Engines Advisors L.L.C. purchased a new position in Bristol-Myers Squibb in the 3rd quarter valued at about $241,000. Rafferty Asset Management LLC lifted its stake in Bristol-Myers Squibb by 7.6% in the 3rd quarter. Rafferty Asset Management LLC now owns 224,040 shares of the biopharmaceutical company’s stock valued at $13,003,000 after buying an additional 15,770 shares in the last quarter. Finally, QRG Capital Management Inc. purchased a new position in Bristol-Myers Squibb in the 3rd quarter valued at about $30,399,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Trading Down 0.7 %

Shares of BMY stock traded down $0.28 on Friday, reaching $41.20. 14,271,103 shares of the stock were exchanged, compared to its average volume of 14,094,110. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The business’s 50 day moving average price is $44.50 and its 200 day moving average price is $48.73. Bristol-Myers Squibb has a twelve month low of $39.91 and a twelve month high of $66.38.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm had revenue of $11.87 billion during the quarter, compared to analysts’ expectations of $11.45 billion. During the same period in the previous year, the company earned $2.05 earnings per share. Bristol-Myers Squibb’s quarterly revenue was up 4.7% compared to the same quarter last year. As a group, analysts expect that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Wells Fargo & Company raised their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. Barclays reduced their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Finally, BMO Capital Markets reduced their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $60.00.

Check Out Our Latest Report on BMY

Bristol-Myers Squibb Profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured Articles

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYFree Report).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.